Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 97

1.

[Safety and pharmacokinetics of 400 and 600 mg arbekacin sulfate to healthy male volunteers].

Sunakawa K, Hori S.

Jpn J Antibiot. 2013 Apr;66(2):97-109. Japanese.

PMID:
23951728
2.

[Arbekacin sulfate concentrations in peripheral lymph and in serum after intravenous injection: report of four cases].

Hayashi M, Ooi K, Yamada S, Wakabayashi H, Imanishi T, Kondo M, Nishii M, Ikawa K, Morikawa N.

Jpn J Antibiot. 2012 Jun;65(3):207-15. Japanese.

PMID:
23173295
3.

[Evaluation of once-daily administration of arbekacin. Experimental study and determination of pharmacokinetic properties in man].

Totsuka K, Shimizu K, Mitomi N, Niizato T, Araake M.

Jpn J Antibiot. 1994 Jun;47(6):676-92. Japanese.

PMID:
8072176
4.

Clinical efficacy and safety of arbekacin sulfate in patients with MRSA sepsis or pneumonia: a multi-institutional study.

Matsumoto T, Hanaki H, Kimura T, Nemoto M, Higashihara M, Yokota H, Oda S, Akiyama N, Miyao N, Yoshida M, Yukioka T, Soma K, Ohyashiki K, Suzuki Y, Arai T, Ikegami K, Ichiwata T, Otsuka Y, Kobayashi M, Totsuka K, Sunakawa K; ABK Dose Finding Study Group.

J Infect Chemother. 2013 Feb;19(1):128-37. doi: 10.1007/s10156-012-0519-z. Epub 2012 Dec 22.

PMID:
23263188
5.

[Evaluation of once a day of arbekacin administration to neonates as a new object of peak concentration].

Kinoshita D.

Kansenshogaku Zasshi. 2010 Nov;84(6):727-33. Japanese.

PMID:
21226325
7.

Double-blind evaluation of the safety and pharmacokinetics of multiple oral once-daily 750-milligram and 1-gram doses of levofloxacin in healthy volunteers.

Chien SC, Wong FA, Fowler CL, Callery-D'Amico SV, Williams RR, Nayak R, Chow AT.

Antimicrob Agents Chemother. 1998 Apr;42(4):885-8.

8.

Pharmacokinetics of duloxetine hydrochloride enteric-coated tablets in healthy Chinese volunteers: a randomized, open-label, single- and multiple-dose study.

Zhao RK, Cheng G, Tang J, Song J, Peng WX.

Clin Ther. 2009 May;31(5):1022-36. doi: 10.1016/j.clinthera.2009.05.005.

PMID:
19539103
9.

[Attenuation of arbekacin-induced nephrotoxicity in rats by pazufloxacin mesilate].

Kizawa K, Miyazaki M, Nagasawa M, Ogake N, Nagai A, Sanzen T, Kawamura Y.

Jpn J Antibiot. 2003 Feb;56(1):44-54. Japanese.

PMID:
12723398
10.

Pharmacokinetics of dexloxiglumide after administration of single and repeat oral escalating doses in healthy young males.

Persiani S, D'Amato M, Makovec F, Tavares IA, Bishai PM, Rovati LC.

Int J Clin Pharmacol Ther. 2002 May;40(5):198-206.

PMID:
12051571
11.

Dosage regimen of arbekacin for methicillin-resistant Staphylococcus aureus infection in newborns and infants.

Yoshida K, Minowa H, Ebisu R, Uchida Y, Takahashi Y, Yoshioka A.

Pediatr Int. 2004 Dec;46(6):645-9.

PMID:
15660861
12.

Pharmacokinetics and pharmacodynamics of once-daily arbekacin during continuous venovenous hemodiafiltration in critically ill patients.

Ikawa K, Morikawa N, Suyama H, Ikeda K, Yamanoue T.

J Infect Chemother. 2009 Dec;15(6):420-3. doi: 10.1007/s10156-009-0717-5. Epub .

PMID:
20012736
13.

A single-dose, three-period, six-sequence crossover study comparing the bioavailability of solution, suspension, and enteric-coated tablets of magnesium valproate in healthy Mexican volunteers under fasting conditions.

Marcelín-Jiménez G, Angeles-Moreno AP, Contreras-Zavala L, Morales-Martínez M, Rivera-Espinosa L.

Clin Ther. 2009 Sep;31(9):2002-11. doi: 10.1016/j.clinthera.2009.09.016.

PMID:
19843490
14.

[Clinical efficacy of arbekacin on MRSA pneumonia].

Kawashima T, Shishibara T, Nakamura H, Kuriyama T, Kanno S, Watanabe M, Kikuchi N, Kunitomo F, Yamagishi F, Mizutani F, et al.

Jpn J Antibiot. 1994 Jun;47(6):741-50. Japanese.

PMID:
8072183
15.

The efficacy and safety of high-dose arbekacin sulfate therapy (once-daily treatment) in patients with MRSA infection.

Yamamoto Y, Izumikawa K, Hashiguchi K, Fukuda Y, Kobayashi T, Kondo A, Inoue Y, Morinaga Y, Nakamura S, Imamura Y, Miyazaki T, Kakeya H, Yanagihara K, Kohno S.

J Infect Chemother. 2012 Apr;18(2):241-6. doi: 10.1007/s10156-012-0397-4. Epub 2012 Mar 8.

PMID:
22398881
16.

Linagliptin, a dipeptidyl peptidase-4 inhibitor in development for the treatment of type 2 diabetes mellitus: a Phase I, randomized, double-blind, placebo-controlled trial of single and multiple escalating doses in healthy adult male Japanese subjects.

Sarashina A, Sesoko S, Nakashima M, Hayashi N, Taniguchi A, Horie Y, Graefe-Mody EU, Woerle HJ, Dugi KA.

Clin Ther. 2010 Jun;32(6):1188-204. doi: 10.1016/j.clinthera.2010.06.004.

PMID:
20637971
17.

Safety and clinical pharmacokinetics of nemonoxacin, a novel non-fluorinated quinolone, in healthy Chinese volunteers following single and multiple oral doses.

Guo B, Wu X, Zhang Y, Shi Y, Yu J, Cao G, Zhang J.

Clin Drug Investig. 2012 Jul 1;32(7):475-86. doi: 10.2165/11632780-000000000-00000.

PMID:
22650326
18.

Pharmacokinetic-pharmacodynamic relationship of arbekacin for treatment of patients infected with methicillin-resistant Staphylococcus aureus.

Sato R, Tanigawara Y, Kaku M, Aikawa N, Shimizu K.

Antimicrob Agents Chemother. 2006 Nov;50(11):3763-9.

19.

[Clinical efficacy of arbekacin on MRSA infections].

Ichiyama S, Shimokata K.

Jpn J Antibiot. 1994 Jun;47(6):731-5. Japanese.

PMID:
8072181
20.

Evaluation of arbekacin anti-MRSA agents for adult in Japan.

Hamada Y, Tamura K, Koyama I, Seki M, Yago K, Sunakawa K, Kuroyama M.

Jpn J Antibiot. 2012 Aug;65(4):221-34.

PMID:
23259253
Items per page

Supplemental Content

Write to the Help Desk